OMVOH

This brand name is authorized in Austria, France, Croatia, Ireland, Italy, Japan, Lithuania, United States

Active ingredients

The drug OMVOH contains one active pharmaceutical ingredient (API):

1 Mirikizumab UNII Z7HVY03PHP - MIRIKIZUMAB

Mirikizumab is a humanised IgG4 monoclonal, anti-interleukin-23 (anti-IL-23) antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. In humans, selective blockade of IL-23 was shown to normalise production of effector cytokines, including IL-17A, IL-17F and IL-22 that drive inflammatory disease. Read about Mirikizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OMVOH Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AC24		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC24

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: FR	Base de données publique des médicaments	Identifier(s): 62045244, 62404327, 68364081
Country: IT	Agenzia del Farmaco	Identifier(s): 050695016, 050695028, 050695030, 050695042, 050695055, 050695067
Country: JP	医薬品医療機器総合機構	Identifier(s): 23994A5A1026, 23994A5G1029, 23994A5G2025
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097213, 1097214, 1097215, 1097216, 1097217, 1097218
Country: US	FDA, National Drug Code	Identifier(s): 0002-7575, 0002-8011, 0002-8870